methotrexate / Generic mfg. - LARVOL DELTA

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). (PubMed, J Clin Oncol) - "Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point was not met, but 17% of all enrolled patients and 48% of the AS group avoided cystectomy without metastatic disease."

Journal • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer • ERCC2 • FANCC • RB1

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. (PubMed, N Engl J Med) - P3 | "The combination of post-transplantation cyclophosphamide and a calcineurin inhibitor led to longer GVHD-free, relapse-free survival than standard prophylaxis after transplantation from a matched related donor with either reduced-intensity or myeloablative conditioning in patients with blood cancers. (Funded by the Australian Government Medical Research Future Fund and others; ALLG BM12 CAST Australian-New Zealand Clinical Trials Registry number, ACTRN12618000505202.)."

Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Transplantation

Phase I trial of a novel first-in-class drug ONC201 as a post-transplant maintenance for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (ASH 2025) - P1 | "GVHD prophylaxis included tacrolimus and methotrexate with or withoutantithymocyte globulin. ONC201 was well tolerated with no observed DLT and a manageable safety profile. The AEprofile was not different from AEs expected in a post-transplant population. Rates of cytopeniaswere low."

Clinical • P1 data • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Myelodysplastic Syndrome • Neutropenia • Thrombocytopenia • Transplantation • ASXL1 • BCOR • DRD2 • STAG2 • TP53 • U2AF1

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ASH 2025) - P1/2 | "Background : With standard high-dose methotrexate (HDMTX) and cytarabine (HDAraC)-basedinductions, half of the patients achieved complete response (CR)...Responders received two cycles of HDAraCfollowed by HD thiotepa-busulfan and ASCT... Both arms met the predetermined threshold of efficacy with 86% and 82% of CR/CRurates in the lenalidomide and ibrutinib arm, respectively. R-MPV plus a BTK-inhibitor or animmunomodulatory drug constitutes an interesting first-line induction for PCNSL patients up to 65 years.Correlation of patient, disease and lymphoid subpopulations characteristics with response in eachtreatment arm will be explored to guide the choice of the targeted therapy. Ancillary studies regardingthe prognostic impact of baseline and end of induction levels of cytokines in the CSF, ctDNA inplasma/CSF and radiomic features, as biomarkers of response, are planned."

Clinical • IO biomarker • P2 data • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Mental Retardation • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome • CD4 • ICOS • PD-1

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies (ASH 2025) - P1 | "Preventing GVHD followingalloHSCT typically requires multi-agent immunosuppression, commonly involving methotrexate or post-transplant cyclophosphamide (PTCy) in combination with a calcineurin inhibitor and other agents.However, pharmacologic immunosuppression impairs immune reconstitution and heightens the risk oforgan toxicity, infection, and disease relapse. The low infection rates observed suggest that the cellular composition of Orca-Qcan control GVHD and accelerate immune reconstitution even without pharmacologicalimmunosuppression. The Phase 1 study continues to enroll patients to further confirm these results."

Clinical • Metastases • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Oncology • CD4 • CD8

Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden. (PubMed, Pediatr Blood Cancer) - P, P3, P3/4 | "The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol."

Journal • Acute Lymphocytic Leukemia • Diabetes • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Oncology • Pediatrics

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. (PubMed, Cureus) - "Only studies involving adult patients with RA treated by approved JAKis (baricitinib, tofacitinib, upadacitinib, peficitinib, and filgotinib) were included...JAKis consistently demonstrated superior responses compared with placebo and methotrexate, with higher American College of Rheumatology 20% response rates, improved disease activity scores, reduced radiographic progression, and enhanced patient-reported outcomes. In head-to-head comparisons, baricitinib and upadacitinib demonstrated advantages over adalimumab across multiple efficacy domains...Nonetheless, their use requires individualized, risk-stratified decision-making, with particular caution in patients at elevated cardiovascular or malignancy risk. Ongoing long-term studies and real-world data remain essential to further define their benefit-risk profile and optimize their integration into personalized RA care."

Journal • Review • Cardiovascular • Herpes Zoster • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Varicella Zoster

Clinical course and therapeutic needs in colonic Crohn’s disease: A retrospective comparison with ileal Crohn’s disease and ulcerative colitis. (ECCO-IBD 2026) - "Descriptive and survival analyses were performed to assess the use of immunosuppressants (thiopurines, methotrexate, cyclosporine, tofacitinib, upadacitinib, and filgotinib), biologics (anti-TNF agents, vedolizumab, ustekinumab), surgery (abdominal and perianal), hospitalizations, and complications (progression to stricturing/penetrating phenotype and/or need for surgery). Conclusion CCD is predominantly inflammatory at diagnosis and throughout its course; however, it exhibits medical and surgical requirements comparable to those of ICD and differs from UC. This may be largely attributable to the high prevalence of associated perianal disease"

Retrospective data • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • Ulcerative proctitis

Filgotinib treatment of calcinosis in centromere-antibody-positive systemic sclerosis (PubMed, Z Rheumatol) - "Methotrexate (MTX) and analgesics were not effective. Sclerodactyly has resolved, and hand function continues to improve. The clinical and radiological response merit further enquiry of Janus kinase (JAK) inhibitors in centromere-antibody-positive LCSSc."

Journal • Immunology • Metabolic Disorders • Pain • Scleroderma • Systemic Sclerosis

COMPARATIVE ANALYSIS OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL VS MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "GVHD prophylaxis consisted of cyclosporine plus methotrexate for MSD transplants, and post-transplant cyclophosphamide on days +3/+4 followed by cyclosporine and mycophenolate for haploidentical HSCT...No patient received letermovir prophylaxis, as it only became available in Mexico after 2025... CMV reactivation was significantly more frequent after haploidentical transplantation, although the timing of reactivation and CMV-related clinical presentation were similar across donor types. Overall survival did not differ according to donor type; however, CMV reactivation was associated with inferior long-term survival. These findings suggest that CMV reactivation represents a clinically relevant event influencing outcomes after allogeneic hematopoietic stem cell transplantation, beyond donor type alone"

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation

THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY (EBMT 2026) - "GVHD prophylaxis included ATG (6 mg/kg) plus low-dose PTCy (50 mg/kg), combined with cyclosporine, mycophenolate mofetil, and a short course of methotrexate...Letermovir was used for CMV prophylaxis; CMV reactivation occurred in 7 patients and EBV reactivation in 16, all resolving with ganciclovir, foscarnet, or rituximab... These data suggest that the TBF+ATG/PTCy regimen is feasible for haplo-HSCT in ALL, with manageable transplant-related toxicity. We will further evaluate the regimen by expanding the patient cohort and extending follow-up, which are essential for efficacy and safety analysis."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Mucositis • T Acute Lymphoblastic Leukemia • Transplantation

ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: SINGLE CENTRE EXPERIENCE (EBMT 2026) - "All transplants used peripheral blood as stem cells source and received antifungal and antiviral prophylaxis (letermovir for CMV-seropositive since available), as well as graft-versus-host disease (GVHD) prophylaxis with different regimens...Four received radiotherapy and 2 splenectomy.Seven patients received pre-transplant ruxolitinib; two responded to treatment: one had initial response that later lost, and the other one switched to momelotinib because of secondary anemia.Regarding donor type: 40% (6/15) were from matched related donors, 40% (6/15) mismatch unrelated, 13.3% (2/15) matched unrelated and 6.6% (1/15) haploidentical.Most commonly conditioning regimen was fludarabine-busulfan. Four patients received TBF (thiotepa, busulfan and fludarabine) and the rest other regimens (BuCy, FluMel).For GVHD prophylaxis, cyclosporine A was mainly used in combination with other immunosuppressants (methotrexate, mycophenolate mofetil)... Our cohort supports that AHSCT in..."

Clinical • Chronic Graft versus Host Disease • Essential Thrombocythemia • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Myelofibrosis • Polycythemia Vera • Transplantation • ASXL1 • CALR • JAK2 • TP53

Immuneai-CMV (Phase-I): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT (TCT-ASTCT-CIBMTR 2026) - "Introduction Post-transplant cyclophosphamide (PTCy) is widely used for GVHD prophylaxis after allogeneic hematopoietic cell transplantation (HCT), yet its impact on cytomegalovirus (CMV) infection risk varies across subgroups...Objectives To identify patient phenotypes with differential CMV risk and heterogeneous effects of PTCy versus methotrexate (MTX)–based GVHD prophylaxis, enabling precision prophylaxis selection...In the day +100 landmark cohort, the model achieved AUC ≈ 0.76, and targeting the top 20–30% by predicted risk captured ~70% of post-day +100 CMV events, supporting risk-guided letermovir continuation and cost savings...4. Interpret clinically actionable metrics (absolute risk reduction, number needed to harm) to support evidence-based shared decision-making in HCT prophylaxis selection."

Heterogeneity • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease

TREOSULFAN-FLUDARABINE AS A REDUCED INTENSITY CONDITIONING ALTERNATIVE TO BUSULFAN-FLUDARABINE FOR ADULT ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE-CENTER, EARLY REAL-LIFE CLINICAL AND ECONOMICAL COMPARATIVE OUTCOMES (EBMT 2026) - " We retrospectively reviewed all allo-HCTs performed between 2021 and 2025 using FT10 or FB2 conditioning, both combined with anti-lymphocyte globulin ((ATG) Thymoglobulin 5 mg/kg or Grafalon 30 mg/kg), for adults with AML or MDS. Transplant practices were identical across the study period: peripheral blood stem cell grafts, ciclosporine + methotrexate for GVHD prophylaxis, letermovir prophylaxis, and unchanged center-level procedures and teams... Despite being used in a substantially higher-risk population, FT10 achieved early post-transplant outcomes comparable to FB2, with a lower burden of early unplanned healthcare costs. These findings support the feasibility and cost effectiveness of FT10 as a reduced-toxicity RIC option for AML/MDS."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Hepatology • Immunology • Transplantation

MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH, and..."

Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

SINGLE-CENTER RETROSPECTIVE CLINICAL STUDY ON THE CONDITIONING REGIMEN OF DECITABINE, THIOTEPA, BUSULFAN, AND FLUDARABINE (DTBF) COMBINED WITH ATG/PTCY FOR ALTERNATIVE DONOR TRANSPLANTATION IN MYELODYSPLASTIC NEOPLASMS (EBMT 2026) - "Thiotepa has been demonstrated favorable safety and efficacy in conditioning regimens for transplantation.However, no research data have been reported yet on the DTBF conditioning regimen combined with anti-thymocyte globulin (ATG)/post-transplantation cyclophosphamide (PTCy) in alternative donor HSCT for adult MDS...The GVHD prophylaxis regimen was based on ATG (7.5 mg/kg) combined with low-dose PTCy (29mg/kg), supplemented with cyclosporine, mycophenolate mofetil, and short-course methotrexate...All patients received letermovir for cytomegalovirus (CMV) infection prophylaxis... The preliminary data indicate that the DTBF + ATG/PTCy conditioning regimen demonstrates favorable efficacy and safety for alternative donor-HSCT in adult MDS patients.Future evaluations will involve expanding the patient cohort and extending the follow - up periods."

Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Mucositis • Myelodysplastic Syndrome • Stomatitis • Transplantation

Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation (TCT-ASTCT-CIBMTR 2026) - "Prior studies comparing letermovir (LET) and high-dose valacyclovir (VAL) for CMV prophylaxis primarily included high-risk patients, such as those with haploidentical or mismatched unrelated donors receiving post-transplant cyclophosphamide (PTCy)...Tacrolimus/methotrexate was the most frequent GVHD prophylaxis (65%)... No significant difference was observed in CMV infection rates between LET and VAL prophylaxis, although the incidence trended lower with LET. LET was associated with a higher rate of HHV-6 reactivation. Rates of acute and chronic GVHD, as well as 6-month survival, did not differ between groups."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma. (PubMed, J Neurooncol) - "Reduced-dose WBRT (23.4 Gy) combined with a response-adapted focal boost was associated with favorable survival and sustained functional preservation, even in elderly or low-PS patients. This strategy may be an effective and feasible consolidation option for frail older patients with PCNSL."

Journal • Retrospective data • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial. (PubMed, Br J Haematol) - "In this prospective, multicentre clinical trial, we evaluated zanubrutinib combined with lenalidomide, temozolomide and rituximab monoclonal antibody ± methotrexate (RLZT ± MTX) as first-line treatment for primary central nervous system lymphoma. RLZT ± MTX demonstrated good efficacy and safety, especially for elderly patients who cannot undergo intensive chemotherapy."

Journal • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Mucous Membrane Pemphigoid After Anti-PD-1 Therapy: Risk-Stratified Management and Treatment Outcomes. (PubMed, Int J Dermatol) - "Overall, doxycycline plus TCS produced the best low-risk response: 5/10 low-risk patients were treated with doxycycline plus TCS; all five achieved complete remission (CR) at least at one anatomic site (3/5 CR at all sites, 2/5 CR with partial response (PR) at different sites). High-risk MMP required escalation with methotrexate, rituximab, and/or intravenous immunoglobulin (IVIg)...Discontinuation of anti-PD-1 is not always required. When anti-PD-1 therapy continuation is clinically prioritized, a systemic steroid-based regimen can stabilize MMP and facilitate completion of immunotherapy."

Journal • Review • Immunology • Oncology

Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA). (PubMed, BMJ Open) - P | "Key factors for therapy changes in patients with RA treated with tofacitinib were lack of efficacy and intolerance. Higher patient satisfaction was associated with a reduced probability of treatment changes, while increased GC doses led to a higher likelihood of step-ups/switches. Patients demonstrated a marked reduction in disease activity for up to 24 months, along with improvements in functional ability, pain and quality of life. Observed AEs were consistent with the known safety profile of tofacitinib."

Journal • Observational data • Real-world evidence • Fatigue • Immunology • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology

Combination of Methotrexate and Mycophenolate mofetil for Refractory Uveitis & Scleritis: A Case Series. (PubMed, Retin Cases Brief Rep) - "The combination of oral methotrexate and mycophenolate mofetil can be a useful alternative in patients resistant to conventional immunosuppression."

Journal • Idiopathic Arthritis • Immunology • Ocular Inflammation • Ophthalmology • Rare Diseases • Rheumatology • Scleritis • Uveitis

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL). (PubMed, Neuro Oncol) - "R-MVP/i was well tolerated and associated with excellent disease control and survival."

Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Thrombocytopenia • Transplantation

Clinical characteristics, management, and prognosis of pembrolizumab-induced immune-related oral mucositis. (PubMed, Front Immunol) - "Refractory disease occasionally required immunomodulatory agents such as methotrexate (16.7%) or infliximab (11.1%). Corticosteroids are effective, and immunosuppressants can be used for refractory cases. Recovery is typically within weeks and rechallenge is feasible for select patients."

Journal • Review • Dental Disorders • Gastrointestinal Disorder • Immunology • Mucositis • Oncology • Pain • Stomatitis

Adult-Onset Still's Disease(AOSD) With Features Suggestive of Macrophages Activation Syndrome in Young Female: A Rare Case Report From Nepal. (PubMed, Clin Case Rep) - "Following the confirmation of AOSD, she received intravenous methylprednisolone pulse therapy, leading to dramatic clinical and biochemical improvement, including a significant decline in ferritin. She was transitioned to oral prednisolone and stabilized for discharge with a plan to initiate methotrexate as a steroid-sparing agent...The atypical presentation with predominant peripheral edema preceding fever and the laboratory finding of elevated CRP with normal ESR are noteworthy. Early recognition, prompt initiation of immunosuppressive therapy, and vigilant monitoring for MAS are crucial to reducing morbidity and mortality in this challenging condition."

Journal • Critical care • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Otorhinolaryngology • Rheumatology • Septic Shock • CRP